A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Recruiting now Phase 1/2 NCT07223047
Run by Bristol-Myers Squibb · for 18 and older · All sexes
What this study is about
The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies
Who can join (things the study team will check)
✅ You may be able to join if…
- Participants must have a histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with a known Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration (mutation or amplification).
- Participants must, for Arm D, have a PD-L1 expression (≥50%).
- Participants must have previously received, be ineligible for, or decline (after having been provided adequate information to make an informed decision) the protocol defined standard of care (SoC) treatments.
🚫 You may not be able to join if…
- Participants must not have untreated central nervous system (CNS) metastases.
- Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment.
- Participants must not have a history of, or any evidence of, interstitial lung disease or active, non-infectious pneumonitis. A history of radiation pneumonitis in the radiation field is permitted.
- Participants must not have a history of prior severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN).
- Other protocol-defined Inclusion/Exclusion criteria apply.
Where this trial is running
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- NEXT Oncology, San Antonio, Texas, United States
- START Mountain Region, West Valley City, Utah, United States
- NEXT Virginia, Fairfax, Virginia, United States
- BC Cancer Vancouver, Vancouver, British Columbia, Canada
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
- Local Institution - 0006, Badalona, Barcelona [Barcelona], Spain
- Local Institution - 0008, Hortaleza, Madrid, Spain
Who to contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07223047.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.